Predilife Restructures Its Workforce and Focuses Entirely on MammoRisk in Europe and the United States
Predilife, a specialist in risk prediction solutions for diseases, outlines its strategic orientation focusing on three main areas: MammoRisk in Europe and the United States, as well as its multi-disease predictive tests for employees. The company also announces a resizing of its internal operations.
Strategic Focus and Clinical Studies
Predilife is concentrating its efforts on three main assets. In Europe, MammoRisk is undergoing a clinical study with a publication timeline of approximately 18 months, a period deemed sufficient to attract potential industrial partners. In the United States, the FDA submission for DenSeerisk, which incorporates MammoRisk, is underway. Concurrently, the multi-disease predictive tests designed for corporate health assessments have proven their commercial viability, covering nearly 10,000 employees and securing agreements with leading brokers and major companies across various sectors.
Internal Operations and Financial Strategy
The internal operation of tests for employees, currently running at a loss, will be discontinued as part of a restructuring planned for mid-April 2026. This action will result in a significant reduction of the workforce involved and aims to limit monthly cash consumption. Following the disbursement of the 2025 research tax credit, the company's cash reserves will be approximately 300 kE with an estimated cash burn of 40 kE per month, providing a cash runway until December 2026. The company will publish its 2025 annual results by May 15, 2026, and its annual financial report by May 30, 2026.
